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license (http://creativepocampal neurogenesis in mice. We investigated whether these chemokines selectively associate with
memory in individuals with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia.
Methods: MCP-1 and eotaxin-1 were assayed in controls, MCI, and AD dementia patients with vary-
ing phenotypes (n 5 171). A subset of 55 individuals had magnetic resonance imaging (MRI) scans
available. Composite scores for cognitive variables were created, and medial temporal lobe volumes
were obtained.
Results: An interaction was noted between MCP-1 and eotaxin-1, such that deleterious associations
with memory were seen when both chemokines were elevated. These associations remained signif-
icant after adding APOE genotype and comparison (non-chromosome 17) chemokines into the
model. These chemokines predicted left medial temporal lobe volume and were not related to other
cognitive domains.
Discussion: These results suggest a potentially selective role for MCP-1 and eotaxin-1 in memory
dysfunction in the context of varied MCI and AD dementia phenotypes.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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The role of peripheral inflammation in the pathogenesis
of neurodegenerative diseases is complex and controversial,
but accumulating evidence suggests that immune-mediated
processes may underlie and promote Alzheimer’s disease
(AD) phenotypes [1,2]. Clarifying how and which specific
inflammatory processes impact memory performance is ofthor. Tel.:11-720-848-7015; Fax:11-303-724-2300.
ianne.bettcher@ucdenver.edu
16/j.dadm.2016.05.004
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).particular importance, as animal models have consistently
linked chronic elevations in pro-inflammatory cascades
with untoward cognitive outcomes and hippocampal
dysfunction [3].
Within the context of pro-inflammatory process, specific
chemokines have recently garnered research attention as po-
tential modulators of memory function both in aging and AD.
Monocyte chemotactic protein-1 (MCP-1; CCL2) and
eotaxin-1 (CCL11) are both members of the C–C chemokine
family clustered closely on the long arm of chromosome 17
and have been linked with memory impairment (eotaxin-1)
[4], age at onset in familial AD (eotaxin-1) [5], senescenceimer’s Association. This is an open access article under the CC BY-NC-ND
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models of aging and AD. In a seminal study using a parabi-
osis model, Villeda et al. [8] identified systemic chemokines
in plasma, including MCP-1 and eotaxin-1, that correlated
with reduced neurogenesis in both aged mice and hetero-
chronic parabionts (i.e., an older mouse surgically connected
to a younger mouse). Moreover, when plasma eotaxin-1
levels were increased in vivo in young mice, impaired spatial
learning, and memory was observed on behavioral tasks.
Although these important studies point to a possible role of
MCP-1 and eotaxin-1 in aging and AD, few studies have ad-
dressed this question in humans [9], and no study has exam-
ined thesemarkers with respect to episodic memory functions
in older adults. As such, it remains unclear whether peripheral
MCP-1 and eotaxin-1 levels are sensitive to verbal or visual
memory difficulties in older adults, and whether this associa-
tion with cognition generalizes to nonmemory domains.
The goal of this study was to assess whether MCP-1 and
eotaxin-1 levels predicted memory functions in older adults
with mild cognitive impairment (MCI) and Alzheimer’s dis-
ease dementia. We hypothesized that higher eotaxin-1 and
MCP-1 levels would be associated with poorer memory per-
formance on both verbal and visual memory tasks. We
further examined whether: (1) the association of eotaxin-1
and MCP-1 levels with cognitive functions were specific to
memory and (2) chemokines outside of the chromosome
17 cluster would similarly predict memory functions. This
allowed us to determine both the sensitivity and specificity
of our findings. Finally, in an exploratory analysis, we
further examined the association of these chemokines with
medial temporal lobe structures.Table 1
Participant characteristics and neuropsychological assessment
Demographic and
Cognitive Variables
Healthy controls
MCI and AD
dementia phenotypes
Overall group
Mean (SD) Mean (SD)
Age (y) 75.6 (7.1) 67.8 (10.4)
Gender (% female) 50% 55%
Education (y) 17.9 16.5
CDR (%) 0:100% 0.5:53.6%
1.0:37.6%
2.0:8.7%
Eotaxin levels (pg/mL) 156.7 (48.9) 172.3 (66.1)
MCP-1 levels (pg/mL) 115.1 (19.6) 102.3 (36.7)
IP-10 levels (pg/mL) 495.4 (301.0) 542.5 (526.9)
MDC levels (pg/mL) 954.1 (319.6) 1085.3 (502.0)
TARC levels (pg/mL) 152.3 (155.0) 190.9 (136.4)
MMSE 29.2 (1.1) 22.4 (5.4)
CVLT-short form 100 Recall 7.4 (1.9) 2.3 (2.6)
CVLT-short form D-prime 3.3 (0.4) 1.7 (1.0)
Benson figure recall 12.5 (2.1) 3.8 (3.8)
Abbreviations: MMSE, mini mental status examination; CVLT, Califor-
nia Verbal Learning Test-II.2. Methods
2.1. Participants
A sample of 151 carefully phenotyped older adults
meeting the National Institute on Aging—Alzheimer’s As-
sociation (NIA-AA) criteria for either mild cognitive impair-
ment [10] or probable dementia due to AD [11] were
included in our AD group. All participants were selected
from the University of California, San Francisco Memory
and Aging Center database based on the availability of
plasma markers of MCP-1 and eotaxin-1 as well as measures
of verbal and visual recall. Both evaluations occurred within
a 90-day period. MCI participants whose phenotypes sug-
gested the presence of other primary etiologies (i.e., vascular
disease; Lewy bodies) were excluded. In addition, 22
healthy controls were included as a comparison group and
were selected based on availability of chemokine markers
and the samememory evaluation as theMCI and AD demen-
tia participants (see below). MCI and AD dementia partici-
pants were recruited from our Alzheimer’s Disease
Research Center and healthy controls were recruited from
our NIH Aging and Cognition study. All patients underwent
a history and physical examination, a structured caregiverinterview, and neuropsychological tests (see Table 1), and
diagnoses were adjudicated in a consensus conference. To
confirm the robustness of our findings, we elected to include
a range of validated AD phenotypes (e.g., posterior cortical
atrophy, logopenic primary progressive aphasia, memory-
predominant AD), severity levels (Clinical Dementia Rating
Scale of 0–2), and ages (early and late onset). Amyloid im-
aging biomarkers, obtained via positron emission tomogra-
phy imaging with Pittsburgh compound B (11C-PiB) [12]
or Florbetapir F 18 (18F-AV-45) [13], were available for 57
individuals, and 55 of 57 were positive. We elected to
exclude the two individuals who were amyloid negative, re-
sulting in a final n of 149 MCI and AD dementia participants
and 22 controls. Of the MCI and AD dementia phenotypes,
102 individuals had a classic memory-predominant pheno-
type, 28 were diagnosed with a logopenic variant of primary
progressive aphasia phenotype, and 19 evidenced a posterior
cortical atrophy phenotype. The study was approved by the
UCSF institutional review board for human research.
Informed consent for the study was provided by the partici-
pants or their assigned surrogate decision makers.
2.2. Measures2.2.1. Global measures
The Clinical Dementia Rating Scale (CDR) was adminis-
tered to all participants to capture overall severity, and the
overall score (0–2) was used as a primary covariate.
2.2.2. Verbal and visual memory
Our primary outcome variable was episodic memory and
was selected due to its consistent and robust associations
with early stages of Alzheimer’s disease [14–17]. Episodic
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memory. For verbal memory, the California Verbal
Learning Test-II Short Form was administered to all partic-
ipants [18]; for data reduction purposes, 10-minute delayed
free recall and recognition dprimewere used as primary vari-
ables of interest. For visual memory, the 15-minute delayed
recall of the Benson figure was used [19]. Using principal
component analysis (minimum eigenvalue 5 0), a single
factor score for memory was created based on aforemen-
tioned verbal and visual memory measures and served as
our primary outcome variable of interest.
2.2.3. Other cognitive measures
To address whether the chemokines were selectively
related to episodic memory, we incorporated principal
component analyses of other cognitive domains using the
same analytic procedure. For the visuospatial domain, our
single factor score included a localization task from the vi-
sual object and space perception battery and the copy condi-
tion of the Benson figure. For the executive control domain,
our single factor score included digit span backward, modi-
fied trail making test, design fluency, and phonemic fluency
[16]. Finally, for the language domain, we included an
abbreviated form of the Boston Naming Test (15-item)
[20] and Peabody Picture Vocabulary Test (16-item).
2.2.4. APOE genotyping
APOE single-nucleotide polymorphism (SNP) genotyp-
ing was carried out by real time polymerase chain reaction
(rtPCR), on an Applied Biosystems 7900HT real-time
PCR machine using the Taqman SNP Genotyping Assay
for rs429358 and rs7412 with identification numbers
C___3084793_20 and C____904973_10, respectively
(Applied Biosystems, Foster City, CA). The protocol was
followed as outlined in the manufacturer’s instructions,
and every assay was performed in duplicate.
2.2.5. Laboratory measures of chemokines
After collection, each blood sample was centrifuged at
2000! g for 15 minutes at 4C with the resultant plasma
divided into 500 mL aliquots and stored at280C. All assays
were conducted following themanufacturer’s protocol forHu-
man Chemokine Panel 1 V-PLEX Plus kit (Meso Scale Diag-
nostics, Rockville, MD). Each multiplex array was scanned
using a MESO QuickPlex SQ 120. Manufacturer supplied
software (Discover Workbench 4.0) was used to quantify
the concentration of eotaxin-1 based on sample dilution and
relative to the supplied in-assay standard curve. Nominal re-
covery for control levels remained between 111%–120%
with a coefficient of variation (CV) ,10%. Standard curve
CVs for patient sample detection range remained ,15%
with standard sample recovery at 100% (1/2 5%) across
all plates. MCP-1 and eotaxin-1 were selected as our primary
chemokines of interest. We elected to focus on these two spe-
cific chemokines given the recent, striking associations with
reduced hippocampal neurogenesis in parabiosis animalmodels [8]. We also included three comparison chemokines
localized to chromosomes 4 (IP-10) and 16 (MDC;
TARC) to examine sensitivity and specificity of findings.
Selection of these comparison chemokines was based on
non-chromosome 17 loci, availability of data (available in
.80% of participants, with CVs ,10%) and presence on
the Meso Scale Chemokine V-PLEX kit.
2.2.6. Neuroimaging
Magnetic resonance imaging (MRI) scans were obtained
on a 3.0-Tesla Siemens (Siemens, Iselin, NJ) TIM Trio
scanner equipped with a 12-channel head coil located at the
UCSF Neuroscience Imaging Center and were available for
a subset of participants (n 5 55). Whole brain images were
acquired using volumetric MPRAGE sequence (repetition
time, echo time, inversion time [TR/TE/TI] 5 2300/2.98/
900 ms, a 5 9). The field of view was 240 ! 256 mm,
with 1! 1mm in-plane resolution and 1-mm slice thickness.
The T1MPRAGE structural MR images were analyzed using
the FreeSurfer 5.1 image analysis suite, which is documented
and freely available for download online at: http://surfer.nmr.
mgh.harvard.edu. Previous publications have provided
detailed descriptions and validation of the software [21–23].
FreeSurfer is a surface-based structural MRI analysis tool
that segmentswhitematter and tessellates both gray andwhite
matter surfaces [24]. For the purposes of this study, the T1
image for each subject was processed through FreeSurfer,
version 5.1 and then individually quality checked for
anatomic accuracy of white or gray matter segmentation.
Common geometric inaccuracies inwhitematter and pial sur-
faces weremanually corrected using the built in editing pack-
ages of FreeSurfer. Medial temporal lobe volumes served as
our primary region of interest (ROI; divided into left and right
hemisphere) and included the entorhinal cortex, parahippo-
campal gyrus, and hippocampus from the Desikan atlas [25].
2.2.7. Statistical analyses
Spearmancorrelationswere conductedbetweenchemokine
markers and demographics. To address our primary hypothesis
regarding an association betweenMCP-1/eotaxin-1 andmem-
ory functions, a series of general linearmodelswere conducted
with demographics (age, gender, education) and phenotype
(controls, individual AD phenotypes) as nuisance covariates,
MCP-1 and eotaxin-1 as covariates of interest, and thememory
factor score as the target outcome variable. MCP-1 and
eotaxin-1 were modeled as both individual main effects as
well as an interaction. The models were repeated with (1)
CDR and APOE included in the model and (2) control chemo-
kines and ultimately applied to the three other cognitive factor
scores. In exploratory analyses, we computed general linear
models with medial temporal lobe volumes as the target
outcome variable. SAS 9.4 was used in all analyses.
3. Results
Higher levels of eotaxin-1 (rs 5 .198, P 5 .01), MCP-1
(rs 5 .205, P 5 .009), and IP-10 (rs 5 .189, P 5 .01) were
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between age and MDC or TARC levels (P. .1). Controlling
for age, only eotaxin-1 levels increased with higher CDR
scores (rs 5 .272, P 5 .01). In terms of specific MCI and
AD dementia phenotypes, on controlling for age, gender,
and CDR, the language predominant phenotype (i.e., logo-
penic variant primary progressive aphasia) showed lower
eotaxin-1 levels than memory-predominant and posterior
cortical atrophy phenotypes, and marginally higher MCP-1
levels than memory-predominant phenotypes (see Fig. 1).3.1. Sensitivity: Relationship between MCP-1, eotaxin-1,
and memory performance
Controlling for demographics and phenotype, higher
levels of MCP-1 were related to lower memory factor scores
across all participants (F(1, 149)5 6.37; t522.52, P5 .01;
unstandardized beta 5 20.0056; SE 5 0.0022; 95% CI 5
20.0100 to 20.0012). No significant effects were found
for themain effect of eotaxin-1 onmemory performance after
controlling for aforementioned covariates (P 5 .69).
We next examined the interaction of both MCP-1 and
eotaxin-1 levels on the memory factor score outcome (see
Table 2 for full results). Controlling for demographics,
phenotype, and individual MCP-1 and eotaxin-1 main
effects, the interaction between MCP-1 and eotaxin-1
significantly predicted worse memory performance
(F(1,143) 5 4.76; t 5 22.18; P 5 .03). This association
strengthened on controlling for CDR and APOE genotype
(F(1,135) 5 9.12, t 5 23.02, P 5 .003).
We also incorporated three control chemokines (IP-10;
MDC; TARC; Only 1 additional non-chromosome 17 che-
mokine was available on the same multiplex; however,
,80% of our participants had detectable levels of this
marker, so it was not included in the analyses.) available
on the same Meso Scale chemokine plex to provide a
preliminary assessment of the specificity of our MCP-1/Fig. 1. The figure displays eotaxin and MCP-1 levels as a function of MCI
and Alzheimer’s disease phenotypes. Abbreviations: AD-Mem, amnestic
phenotype; lvPPA, logopenic variant of primary progressive aphasia pheno-
type; PCA, posterior cortical atrophy phenotype. *Significant between
group difference, P ,.05.eotaxin-1 findings. After controlling for demographics,
CDR, APOE, and the control chemokines, the interaction be-
tween MCP-1 and eotaxin-1 remained predictive of worse
memory performance (F(1,130) 5 7.83; t 5 22.80;
P 5 .006; see Table 2 for full results).
To better understand and visualize the relationship be-
tween the MCP-1! eotaxin-1 interaction and the episodic
memory factor scores, we subdivided eotaxin-1 levels into
quartiles. We regressed the memory factor score over the de-
mographic and CDR variables to create a single residual
measure (i.e., the memory factor score, accounting for the
aforementioned covariates). We then plotted the association
between MCP-1 levels and the memory factor residual score
as a function of eotaxin-1 quartiles (see Fig. 2). Results indi-
cated that the negative association between MCP-1 and
memory scores was strongest in individuals with the highest
quartile of eotaxin-1 levels.
3.2. Specificity: Relationship between MCP-1, eotaxin-1,
and other cognitive domains
Controlling for demographics and phenotype, neither
MCP-1 levels nor eotaxin-1 levels were significantly associ-
ated with the executive function, visuospatial, or language
factors (all P’s . .1). Given that the interaction between
MCP-1 and eotaxin-1 resulted in stronger associations
with the memory factor score, we also tested the effects of
this interaction on the other cognitive domains. The interac-
tion between MCP-1 and eotaxin-1 did not significantly pre-
dict the nonmemory factor scores (all P . .1).
3.3. Exploratory analysis: Relationship between MCP-1,
eotaxin-1, and medial temporal lobe volumes
A small subset of individuals (n5 55; 8 controls, 25MCI;
22 AD dementia) had MRI scans within 6 months of their
blood draws. In an exploratory analysis, we evaluated
whether MCP-1 and eotaxin-1 levels were individually asso-
ciated with the medial temporal lobe volume ROI. Control-
ling for demographics, intracranial volume, and phenotype,
both higher eotaxin-1 (F(1, 44)5 8.69; t522.95, P5 .005;
unstandardized beta525.43; SE5 1.84; 95% CI529.14
to21.72) and MCP-1 (F(1, 46)5 4.45; t522.11, P5 .04;
unstandardized beta 5 28.77; SE 5 4.16; 95%
CI5217.15 to20.40) levels were associated with smaller
left medial temporal lobe volumes. Associations between the
chemokines and right medial temporal lobes did not reach
statistical significance but were in the expected direction
(i.e., inverse associations, P’s , .15). Owing to the small n
of the imaging subsample, we did not explore associations
with other cortical regions.4. Discussion
Our study demonstrates that an interaction between
higher MCP-1 (CCL2) and eotaxin-1 (CCL11) levels pre-
dicts worse verbal and visual episodic memory scores. The
Table 2
Interaction of MCP-1 and eotaxin-1 predicting episodic memory factor scores
Analyses
General linear model results for memory factor score
t-value, unstandardized beta (standard error)
P value95% confidence interval
Interaction analysis (controlling for demographics and phenotype)
MCP-1! eotaxin-1 t 5 22.18, beta 5 20.00007 (SE 5 0.00003) .038
95% CI 5 20.00014 to 20.000007
Interaction analysis* (controlling for demographics, phenotype, CDR, and APOE)
MCP-1! eotaxin-1 t 5 23.02, beta 5 20.00009 (SE 5 0.00003) .003
95% CI 5 20.00014 to 20.000030
Interaction analysis (controlling for demographics, phenotype, CDR, APOE, and control chemokines)
MCP-1! eotaxin-1 t 5 22.80, beta 5 20.00008 (SE 5 0.00003) .006
95% CI 5 20.00014 to 20.000024
NOTE. Memory Factor Scores have a mean of 0 for the entire sample.
*Results remained comparable whether controlling for phenotype and CDR or simply controlling for CDR alone.
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memory is strongest when both inflammatory markers
were elevated. Although studies using mouse models of ag-
ing have linked MCP-1 and eotaxin-1 to memory functions,
this is the first human study to show sensitivity of these che-
mokines to memory dysfunction in a wide range of MCI and
Alzheimer’s disease dementia phenotypes. Moreover, our
study suggests that not only is the association of MCP-1
and eotaxin-1 levels with cognition specific to memory func-
tions, but that these chemokines also appear to be related to
left medial temporal lobe volumes.
An association between memory and chemokines, specif-
ically eotaxin-1 and MCP-1, has been reported in mouse
models of aging and Alzheimer’s disease, and more recently,
a human study identified a haplotype of SNPs on chromo-
some 17 within a chemokine gene cluster, including
eotaxin-1, that associated with age of onset in familial AD
[5]. Although very few studies have been conducted, they
collectively suggest that eotaxin-1 and MCP-1 may be
important markers for pathologic aging [8,26]. In the one
human study on MCP-1 and cognitive decline in AD, higher
levels of this chemokine predicted a faster rate of cognitiveFig. 2. The figure demonstrates the relationship betweenMCP-1 andmemory
as a functionof eotaxin-1 levels. TheVerbal andVisualMemoryFactoryScore
Residual is the memory factor score accounting for demographics and CDR.decline in prodromal AD [9]; however, this study did not
specifically examine its role in episodic memory functions,
and the study’s findings were circumscribed to CSF and
not plasma. It is unclear why this study and our study differ
in terms of plasma MCP-1 results and cognition, although
the studies differ in terms of primary outcome variables
(i.e., rate of cognitive decline versus cross-sectional memory
performance). Our study provides initial evidence for a
modulatory role of MCP-1 and eotaxin-1 on both verbal
and visual memory, independent of APOE genotype and
clinical severity level, in older adults at risk for or showing
clear symptoms of AD.
Mechanisms for how circulating immune markers may
relate to memory functions remain unclear. Accumulating
evidence suggests the possibility of bidirectional links be-
tween the periphery and central nervous system (CNS)
[27,28], including vagal afferent pathways. As noted
recently by Villeda et al. [8], neurogenic niches, including
the subgranular zone of the hippocampus, are located around
blood vessels, leaving open the possibility that systemic
changes in proteins and inflammatory markers may alter
neurogenesis in aging. Although the present study cannot
directly address whether peripheral inflammatory markers
reflect a separate, but mirrored CNS process, or play a direct
role in CNS immune dysregulation, the results provide a
translational link with animal studies that supports a role
for circulating markers in AD clinical phenotypes.
An important aspect of this study was the possible spec-
ificity of the MCP-1 and eotaxin-1 findings on cognition. We
attempted to address this concern in two ways, by (1) exam-
ining the association of these chemokines with other, non-
memory cognitive functions and (2) evaluating whether
comparison chemokines on the MESO-plex localized to
different chromosomes (4 and 16; IP-10, MDC, and
TARC) were associated with episodic memory function.
We found no associations between MCP-1 and eotaxin-1
with other cognitive measures nor did we find relationships
between comparison chemokines and memory functions.
Chemokine families tend to cluster on chromosomes 17, 4,
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represent important loci for memory dysfunction. Consid-
ering that our primary hypotheses focused on MCP-1 and
eotaxin-1 levels and to reduce multiple comparisons, we
did not explore other chromosome 17 chemokines in the pro-
posed study; thus, it is important to highlight that although
our results are suggestive of specificity, they should be
considered preliminary. Future studies should examine the
role of MCP-1 and eotaxin-1 in larger cohorts and also
examine the possible role of other chromosome 17 chemo-
kines in episodic memory function.
Our exploratory analysis in a subset of individuals also
found an association between MCP-1 and eotaxin-1 with
left medial temporal lobe volumes, a region of the brain
known to be affected in early AD [29]. These results are
consistent with the behavioral findings and are particularly
encouraging given that this subanalysis was underpowered
to detect small effects. Given the small sample size of
individuals who obtained an MRI of the brain, we elected
not to examine other regions in the brain. Thus, it is unclear
whether these chemokines predict gray matter volumes in a
more distributed or widespread manner.
Although not a primary goal of the study, it is worth
noting that absolute levels of MCP-1 were not significantly
higher in MCI and AD dementia participants nor did they
correlate with clinical severity level. The literature on in-
flammatory markers at different stages of pathogenesis has
been mixed [30], with no studies to date reporting on inflam-
matory levels as a function of clinical AD phenotype. To
evaluate the robustness of the relationship and to increase
the range in memory scores, we included a wide range of
severity levels and both memory and nonmemory predomi-
nant MCI and AD dementia phenotypes. This limited the
likelihood that strictly memory predominant phenotypes
drove the association between chemokines and memory
functions. Interestingly, differences in both eotaxin-1 and
MCP-1 levels were observed between phenotypes, particu-
larly in relation to language predominant (i.e., logopenic
variant primary progressive aphasia) MCI and AD dementia
phenotypes, which should be explored further in future
studies.
Although our study has numerous strengths, including the
use of a large MCI and AD dementia cohort and incorpora-
tion of multiple memory indices, there are limitations as
well. Amyloid imaging was only available for a subset of in-
dividuals; thus, while we attempted to enrich for AD pathol-
ogy by solely focusing on established phenotypes (e.g.,
typical memory-predominant, posterior cortical atrophy,
and logopenic aphasia), it remains possible that some MCI
individuals did not have underlying AD pathology. In addi-
tion, although the associations between MCP-1 and eotaxin-
1 and memory functions were robust, effect sizes for the
interaction remain relatively small. Whether these chemo-
kines selectively influence hippocampal function and vol-
ume independent of AD also needs further study.In conclusion, there is a potentially selective role for
MCP-1 and eotaxin-1 in episodic memory dysfunction in
the context of a wide array of MCI and Alzheimer’s disease
dementia phenotypes. Moreover, our study suggests that not
only is the association of MCP-1 and eotaxin-1 levels with
cognition specific to memory functions, but these
chemokines also appear to be sensitive to left medial
temporal lobe volumes. Future studies should explore
possible mechanisms of action and elucidate whether
chromosome 17 chemokines more broadly play an integral
role in memory functions and pathological aging.
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1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources.
Although the underlying mechanisms of how MCP-
1 and eotaxin relate to hippocampal function and
episodic memory are in preliminary stages of eval-
uation, recent mouse studies suggest a potentially
direct relationship between these markers and hip-
pocampal neurogenesis. These articles have been
cited.
2. Interpretation: Our findings suggest a potentially
sensitive and selective role for MCP-1 and eotaxin
in memory consolidation across a wide range of
Alzheimer’s disease phenotypes, which corroborates
recent animal literature.
3. Future directions: The article outlines several lines of
inquiry that should be addressed, including (1) the
relationship between peripheral and CNS inflamma-
tion in Alzheimer’s disease; (2) the role of MCP-1
and eotaxin in hippocampal function in humans,
including individuals without Alzheimer’s disease;
(3) the role of chromosome 17 chemokines in
cognitive functioning; (4) whether different AD
phenotypes show different immune and inflamma-
tory profiles.
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